When Canada’s scientists and engineers have the opportunity to succeed, they’re able to make the discoveries that lead to ground-breaking innovations, sustainable economic growth and a stronger middle class. The hard work of these researchers also helps new generations of students master the advanced skills they need for the jobs of tomorrow. That is why the Minister of Science, Kirsty…
Read More
The manuscript describes our results of evaluating activity of darolutamide in enzalutamide-resistant CRPC as well as in androgen receptor (AR) mutants detected in patients after treatment with enzalutamide, abiraterone, or bicalutamide. We found that darolutamide potently inhibits enzalutamide-resistant CRPC both in vitro and in vivo. Moreover, darolutamide supppressed the transcriptional activity of AR mutants identified in the plasma of CRPC patients progressing on traditional therapies...
Read More
Genome BC has invested approximately $850,000 towards two projects that successfully illustrate the application of precision health in our Province’s public healthcare system. These evidence-based projects demonstrate the impact of genomics on healthcare challenges through increased efficiencies and new treatment options. The first project uses genomics to better prevent the spread of “superbugs” in hospitals and care facilities. Carbapenemase-producing organisms…
Read More

Graduate Program in Neuroscience Finds New Leader in Dr. Liisa Galea

Dr. Liisa Galea began her tenure as Director of the Graduate Program in Neuroscience on July 1, taking over from Dr. Tim O’Connor who served the UBC neuroscience community in the role since 2011. “I know I have some big shoes to fill,” says Dr. Galea. A neuroscientist and professor in the Department of Psychology at UBC, Dr. Galea specializes in how sex…
Read More
Alzheimer’s Disease (AD), characterized by accumulation of beta-amyloid (Aβ) plaques in the brain, can be caused by age-related failures to clear Aβ from the brain through pathways that involve the cerebrovasculature. Vascular risk factors are known to increase AD risk, but less is known about potential protective factors. We hypothesize that high-density lipoproteins (HDL) may protect against AD, as HDL…
Read More
Three of Canada’s leading researchers in heart health, brain health and cancer have been singled out by the University of British Columbia Faculty of Medicine for their accomplishments, and for their potential to make further contributions in their fields. The seventh annual Margolese National Heart Disorders Prize will be given to Stanley Nattel of the University of Montreal, for his…
Read More
Dr. Ying Tam is the Director of Preclinical Development at Acuitas Therapeutics, a Vancouver-based pharmaceutical company specializing in systemic delivery of nucleic acid therapeutics. Prior to his career in industry, Dr. Tam held a faculty position in the department of Hematology and Oncology at Rush-Presbyterian Medical Centre in Chicago, Illinois. We sat down with Dr. Tam to discuss his journey…
Read More
A deceptively simple device invented at the University of B.C. is saving lives in the world’s most impoverished places. Called the Phone Oximeter, it clips onto a person’s fingertip and is connected by wire to a smartphone’s audio port. By measuring blood-oxygen levels and heart and breathing rates with unprecedented simplicity, portability and affordability, it’s enabling easier diagnosis of illness…
Read More

cGAS-STING and Cancer: Dichotomous Roles in Tumor Immunity and Development

cGMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) sensing has emerged as a key regulator of innate immune responses to both exogenous and endogenous DNA. Recent studies reveal critical roles for this pathway in natural antitumor immunity across cancer types as well as in immune checkpoint blockade therapy. However, it is also clear that some tumors evade cGAS-STING-mediated immune responses, and…
Read More
Sitka Biopharma Inc., a preclinical biotechnology company focused on developing its breakthrough nanoparticle platform technology to increase absorption of drugs in difficult-to-penetrate tissues, is pleased to announce that Dr. Kristine Swiderek and Dr. Jack Geltosky have joined its Board of Directors. Dr. Kristine Swiderek is the Co-founder and Chief Scientific Officer of venture-backed OncoResponse, focusing in immuno-oncology. She brings deep…
Read More